INDP Indaptus: Earnings per share for the last twelve months
The current EPS TTM level for Indaptus Therapeutics (INDP) demonstrates volatility driven by patent disputes in the field of bacterial immunotherapy. Successes with the Decoy20 system and the prospects of combination therapy are creating positive momentum. However, capital shortages and safety risks during early-stage trials remain critical. The value of -6.95 is recorded as the baseline value determining the company's current financial reference point.
Analytical breakdowns and data insights for company Indaptus Therapeutics Inc (INDP)
- current quotes and average value forecast:
- company stock capitalization data:
- shareholders' equity book value data:
- debt and liquidity data:
Total Debt to Capital Indaptus Therapeutics|INDP - Long-Term Liabilities to Capital|Short-Term Debt to Capital Indaptus|INDP - Company Total Debt Obligations|Debt to Book Capitalization Ratio Indaptus Therapeutics, Inc.|INDP - Company Long-Term Indebtedness|Company Short-Term Debts Indaptus Therapeutics|Quick Ratio indaptusrx.com
- earnings and valuation multiples indicators:
INDP - Net Profit|Expected Profit Indaptus Therapeutics|INDP - Market Cap to Net Income|Projected Price to Earnings Indaptus Therapeutics, Inc.|INDP - Company Value to Earnings Growth Ratio|Enterprise Value to EBITDA Ratio Indaptus Therapeutics, Inc.|INDP - Operating profit EBITDA|Earnings per share for the last twelve months Indaptus Therapeutics|INDP - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months indaptusrx.com|INDP - Earnings per share increase in current year|Expected earnings per share growth for next year Indaptus Therapeutics
Fundamental company analysis:INDP - Indaptus Therapeutics
For Indaptus Therapeutics (INDP), net earnings per share determine the capitalization efficiency of its biopharmaceutical developments. This metric is calculated as the ratio of total annual net income to the number of common shares. By analyzing the fundamental TTM net earnings per share, an investor assesses the business's specific profitability. The stability of this indicator confirms the reliability of diversified biocomponent production chains. The trend of this indicator allows for timely portfolio rebalancing, minimizing the risk of drawdowns.
Direct competitors
ARGX - Earnings per share for the last twelve months|biontech.de (BNTX) - Net earnings per share for the last 12 months|Abivax Pharma (ABVX) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months ADMA Biologics Inc|Net earnings per share for the last 12 months PTGX|Net earnings per share (EPS TTM) Immunovant Therapeutics|Earnings per share for the last twelve months Kiniksa Pharmaceuticals (KNSA)|grifols.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) ADPT (Adaptive Biotechnologies Corporation)|Celldex Therapeutics Inc (CLDX) - Net earnings per one share for the last twelve months|Aurinia Pharma - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioCryst Corp BCRX|Vera Therapeutics, Inc. (VERA) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DNTH|PHVS (Pharvaris) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months ABCL (AbCellera Biologics Inc)|Net earnings per share (EPS TTM) TRML|Net earnings per share (EPS TTM) Precigen Corp (PGEN)|Earnings per share for the last twelve months Pharming Group N.V. PHAR|NKTR (nektar.com) - Earnings per one share for the last 12 months|UPB: Net earnings per share for the last 12 months|Zenas Bio - Earnings per share for the last four quarters|IMNM (Immunome Corp) - Net earnings per share for the last 12 months|Gossamer Bio Corp. (GOSS) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months KalVista Pharmaceuticals|septerna.com (SEPN) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months PVLA (Pieris Pharmaceuticals, Inc.)|SVRA (Savara Inc) - Earnings per share for the trailing year|Rigel Pharmaceuticals Inc - Net earnings per share for the last 12 months|Earnings per share for the last four quarters ANAB (AnaptysBio Inc.)|Astria Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ENGN (engene.com)|RAPT: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Aerovate Therapeutics (JBIO)|Earnings per share for the last twelve months Aclaris|KYTX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) TLSA|Net earnings per share (EPS TTM) cabalettabio.com (CABA)|Earnings per share for the last twelve months Ventyx Biosciences, Inc. VTYX|THTX (Theratechnologies, Inc.) - Earnings per one share for the last 12 months|Avalo Therapeutics Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Eledon Pharmaceuticals, Inc|AGEN (Agenus) - Net earnings per share for the last 12 months|climbbio.com (CLYM) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months ZURA|ATYR (aTyr Pharma Inc) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) ADAG|Net earnings per share for the last four quarters ikenaoncology.com|Net earnings per share (EPS TTM) STTK (Shattuck Labs)|EQ - Net earnings per share for the last 12 months|CNTB - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Immunic, Inc. IMUX|ATRA: Net earnings per share (EPS TTM)|IFRX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months X4 Pharmaceuticals|Earnings per share for the last 12 months ACET (Adicet)|Net earnings per share (EPS TTM) CELU|INmune Bio Inc - Earnings per share for the last 12 months|Earnings per share for the last twelve months Barinthus Bio BRNS|KZR (Kezar Life Sciences Inc) - Earnings per one share for the last 12 months|SABS - Earnings per share for the last twelve months|Earnings per one share for the last 12 months AKTX|ENLV: Net earnings per share (EPS TTM)|Q32 Bio - Earnings per share for the trailing year|GOVX (GeoVax Labs Inc) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Edesa Biotech Corp|Earnings per share for the last twelve months iBio, Inc. (IBIO)|CARM (carismatx.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months XTL Biopharmaceuticals Ltd. XTLB|BOLT - Net earnings per share for the last 12 months|HCW Biologics Inc - Net earnings per share (EPS TTM)|APVO - Net earnings per share (EPS TTM)|AIM (AIM ImmunoTech) - Net earnings per share for the last 12 months|Aditxt, Inc. - Earnings per share for the trailing year|GRI (GRI Bio) - Net earnings per share (EPS TTM)|XORTX Therapeutics Inc (XRTX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months ReShape Lifesciences (HIND)|Net earnings per share for the last 12 months Revelation Biosciences Corp REVB|Earnings per share for the last twelve months Scinai Immunotherapeutics SCNI|CALI - Net earnings per share for the last 12 months|AFMD: Net earnings per share for the last 12 months|ALLK - Net earnings per share (EPS TTM)|hookipapharma.com (HOOK) - Earnings per share for the last twelve months|Earnings per share for the last 12 months IGMS|ITOS (iTeos Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months oceanbiomedical.com OCEA|Net earnings per share (EPS TTM) TCBP|Net earnings per share for the last four quarters Third Harmonic Bio Inc.
